Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735267 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 468
- Enrollment target
NCT00735267: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00735267 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 468 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735267, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 468 participants
- Enrollment target
Study Summary
This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
Interventions
- DRUG PD 0332334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 468 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Why NCT00735267 stopped before completion
NCT00735267 is an interventional study that assigns participants to a tested intervention. The registered 468 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% lower).
The record links to 0 conditions, and to 1 intervention - of which PD 0332334 is the first listed.
NCT00735267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00735267 about?
NCT00735267 is a clinical study titled "A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)". This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.
What is the current status of trial NCT00735267?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 468 participants. The study started on 2008-10. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00735267?
The interventions under investigation include: PD 0332334 (DRUG).
Who is sponsoring clinical trial NCT00735267?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00735267's enrollment target sits among peer trials
468 816th of 2000 higher than 1,185 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03124303 · 468 participants
Interventions for Postoperative Delirium: Biomarker-3
- NCT03901924 · 468 participants · NA
Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
- NCT04482309 · 468 participants · Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- NCT05357170 · 468 participants
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia